Clinical Trial Update: Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating sequential anti-CTLA-4 antibody followed by anti-PD-1 antibody in recurrent or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-CTLA-4 antibody
• Anti-PD-1 antibody

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: UNKNOWN